Table 1 Clinicopathological characteristics between TIVA group and IHA group, before and after propensity-score match
Characteristics |  | TIVA group N = 323 (%) | IHA group N = 2264 (%) | P value | SMD | TIVA group N = 344 (%) | IHA group N = 688 (%) | P value | SMD |
|---|---|---|---|---|---|---|---|---|---|
Age, median (IQR) | Years | 60.0 [51.0, 66.0] | 59.00 [50.0, 66.0] | 0.628 | 0.035 | 60.0 [51.0, 66.0] | 60.0 [51.0, 67.0] | 0.967 | 0.018 |
Gender | Female | 102 (31.6) | 671 (29.6) | 0.517 | 0.042 | 102 (31.6) | 205 (31.8) | 1 | 0.004 |
Tumor Size, median (IQR) | cm | 4.0 [3.0, 6.0] | 5.0 [3.0, 6.0] | 0.012 | 0.152 | 4.0 [3.0, 6.0] | 4.0 [3.0, 6.0] | 0.435 | 0.065 |
Borrmann Type | Type III-IV | 131 (40.6) | 916 (40.5) | 1 | 0.002 | 131 (40.6) | 238 (36.9) | 0.301 | 0.075 |
Differentiated Degree | G3-G4 | 260 (80.5) | 1812 (80.0) | 0.905 | 0.012 | 260 (80.5) | 521 (80.8) | 0.986 | 0.007 |
Tumor Location | Non-AEG | 74 (22.9) | 619 (27.3) | 0.106 | 0.102 | 74 (22.9) | 145 (22.5) | 0.945 | 0.010 |
Operation Type | Laparoscopic | 29 (9.0) | 318 (14.0) | 0.016 | 0.159 | 29 (9.0) | 73 (11.3) | 0.314 | 0.078 |
Radical Degree | R1/R2 | 4 (1.2) | 103 (4.5) | 0.008 | 0.198 | 4 (1.2) | 6 (0.9) | 0.912 | 0.03 |
Lymphadenectomy Degree | D2/D2+ | 291 (90.1) | 1991 (87.9) | 0.303 | 0.069 | 291 (90.1) | 580 (89.9) | 1 | 0.006 |
Operation Time, median (IQR) | min | 230.0 [205.0, 260.0] | 235.0 [205.0, 270.0] | 0.368 | 0.067 | 230.0 [205.0, 260.0] | 230.0 [200.0, 265.0] | 0.928 | 0.007 |
Blood Loss, median (IQR) | ml | 100.0 [50.0, 105.0] | 100.0 [80.0, 150.0] | 0.032 | 0.147 | 100.0 [50.0, 105.0] | 100.0 [80.0, 200.0] | 0.088 | 0.126 |
pT stage | T1 | 68 (21.1) | 491 (21.7) | 0.242 | 0.120 | 68 (21.1) | 140 (21.7) | 0.515 | 0.102 |
T2 | 57 (17.6) | 328 (14.5) | Â | Â | 57 (17.6) | 126 (19.5) | Â | Â | |
T3 | 73 (22.6) | 460 (20.3) | Â | Â | 73 (22.6) | 120 (18.6) | Â | Â | |
T4 | 125 (38.7) | 985 (43.5) | Â | Â | 125 (38.7) | 259 (40.2) | Â | Â | |
pN stage | N0 | 126 (39.0) | 771 (34.1) | 0.125 | 0.143 | 126 (39.0) | 256 (39.7) | 0.917 | 0.048 |
N1 | 60 (18.6) | 372 (16.4) | Â | Â | 60 (18.6) | 108 (16.7) | Â | Â | |
N2 | 52 (16.1) | 417 (18.4) | Â | Â | 52 (16.1) | 106 (16.4) | Â | Â | |
N3 | 85 (26.3) | 704 (31.1) | Â | Â | 85 (26.3) | 175 (27.1) | Â | Â | |
pTNM stage | I | 92 (28.5) | 575 (25.4) | 0.026 | 0.161 | 92 (28.5) | 189 (29.3) | 0.962 | 0.019 |
II | 91 (28.2) | 529 (23.4) | Â | Â | 91 (28.2) | 178 (27.6) | Â | Â | |
III | 140 (43.3) | 1160 (51.2) | Â | Â | 140 (43.3) | 278 (43.1) | Â | Â | |
No. of Positive LNs, median (IQR) | numbers | 2.0 [0.0, 7.0] | 2.0 [0.0, 8.0] | 0.013 | 0.138 | 2.0 [0.0, 7.0] | 2.0 [0.0, 7.0] | 0.806 | 0.034 |
No. of Examined LNs, median (IQR) | numbers | 26.0 [19.5, 35.0] | 27.0 [20.0, 37.0] | 0.065 | 0.159 | 26.0 [19.5, 35.0] | 26.0 [20.0, 36.0] | 0.670 | 0.066 |
Perioperative NSAIDs | Use | 6 (1.9) | 57 (2.5) | 0.598 | 0.045 | 6 (1.9) | 16 (2.5) | 0.701 | 0.043 |
Adjuvant Chemotherapy | Yes | 183 (56.7) | 1370 (60.5) | 0.207 | 0.078 | 183 (56.7) | 377 (58.4) | 0.643 | 0.036 |
Postoperative 30-day complications | Yes | 54 (16.7) | 411 (18.2) | 0.582 | 0.038 | 54 (16.7) | 114 (17.7) | 0.779 | 0.025 |
Postoperative Hospital Stay, median (IQR) | Days | 10.00 [9.00, 12.00] | 10.00 [9.00, 12.00] | 0.992 | 0.031 | 10.00 [9.00, 12.00] | 10.00 [9.00, 12.00] | 0.833 | 0.015 |